He also spoke of his opposition to the 1958 change in wastewater output route to Minamata River. Hosokawas testimony was backed up by a colleague who also told how Chisso officials had ordered them to halt their cat experiments in the autumn of 1959. Hosokawa died three months after giving his testimony. Former factory manager Eiichi Nishida admitted that the company put profits ahead of safety, resulting in dangerous working conditions and a lack of care with mercury. Former Chisso President Kiichi Yoshioka admitted that the company promoted a theory of dumped World War II explosives, though it knew it to be unfounded. The verdict handed down on 20 March 1973 represented a complete victory for the patients of the litigation group:

The defendants factory was a leading chemical plant with the most advanced technology and ... should have assured the safety of its wastewater. The defendant could have prevented the occurrence of Minamata disease or at least have kept it at a minimum. We cannot find that the defendant took any of the precautionary measures called for in this situation whatsoever. The presumption that the defendant had been negligent from beginning to end in discharging wastewater from its acetaldehyde plant is amply supported. The defendant cannot escape liability for negligence. The "sympathy money" agreement was found to be invalid and Chisso was ordered to make one-time payments of ¥18 million ($66,000) for each deceased patient and from ¥16 million to ¥18 million ($59,000 to $66,000) for each surviving patient.
Typical dosages are 500-1000IU three times weekly, or 4,000IU three times weekly for 6–9 months until atrophy is reversed and the dose is reduced to 2,000IU three times weekly. These doses are starting guidelines for treatment, and variable depending on individual response. In off-label use, some urologists prescribe hCG in low doses in combination with Testosterone replacement to preserve fertility.In male children: Also used to treat prepubertal cryptorchidism not due to anatomical obstruction. therapy is usually administered between ages 4 and 9. Urinary preparations
Derived from the urine of pregnant women. Generic
(human) chorionic gonadotropin for injection, USPBrands
Pregnyl (Merck/Schering-Plough)
Follutein
Profasi
Novarel

Recombinant preparations
Generic
choriogonadotropin alfa for injection (recombinant human Chorionic Gonadotropin, r-hCG). Brands
Ovidrel


== References ==